688271 联影医疗
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,907,56617.34%13,800,25210,300,10411,410,7669,238,123
减:营业总成本2,559,73020.02%12,083,5349,385,2729,857,9467,774,181
    其中:营业成本1,536,31723.85%7,312,5825,300,1626,039,1594,769,998
               财务费用41,984-347.88%(30,626)(112,290)(148,887)(98,725)
               资产减值损失(61)15.68%1,30313,843(42,886)(74,747)
公允价值变动收益3,181-108.22%(37,114)37,000(6,063)28,500
投资收益18,43126.86%80,51398,074110,34512,667
    其中:对联营企业和合营企业的投资收益(2,457)-48.75%2,100(5,623)(15,872)(7,651)
营业利润485,97621.87%2,000,3091,366,3562,141,5151,928,243
利润总额481,11920.94%1,981,3951,351,7082,142,2551,919,795
减:所得税费用88,676174.60%137,348109,784164,500269,710
净利润392,4437.36%1,844,0471,241,9241,977,7551,650,086
减:非控股权益(6,426)41.01%(25,253)(19,945)3,462(5,998)
股东净利润398,8697.78%1,869,3011,261,8691,974,2921,656,084

市场价值指针
每股收益 (元) *0.4806.67%2.2801.5402.4002.190
每股派息 (元) *----0.3100.2000.2500.201
每股净资产 (元) *26.6488.27%26.17424.15022.89221.214
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容